C12N 2760/16241
Use of virus, viral particle or viral elements as a vector
C12N2760/16241 (Use of virus, viral particle or viral elements as a vector) appears on 32 US grants and 45 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 45
- Assignees
- 22
- Inventors
- 48
- Latest grant
- 13 Feb 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 0 | 3 |
| 2005 | 1 | 3 |
| 2006 | 0 | 2 |
| 2007 | 1 | 1 |
| 2008 | 2 | 0 |
| 2009 | 4 | 6 |
| 2010 | 0 | 4 |
| 2011 | 4 | 2 |
| 2012 | 2 | 5 |
| 2013 | 3 | 2 |
| 2014 | 6 | 6 |
| 2015 | 2 | 1 |
| 2016 | 3 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 4 |
| 2024 | 1 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/16243Viral genome or elements thereof as genetic vectorIndexing code32
- C12N 2760/16242Virus or viral particle as vehicleIndexing code0
- C12N 2760/16244Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2760/16245Special targeting system for viral vectorsIndexing code0
Recent patents
- Compositions and methods to increase production13 Feb 2024US 11,897,918 B2Seqirus UK Limited
- Recombinant influenza vectors with tandem transcription units23 Jul 2019US 10,358,630 B2Wisconsin Alumni Research Foundation (WARF)
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals12 Jul 2016US 9,387,240 B2Icahn School of Medicine at Mount Sinai
- Methods for the propagation of modified influenza viruses in embryonated eggs31 May 2016US 9,352,033 B2Icahn School of Medicine at Mount Sinai
- Multi plasmid system for the production of influenza virus19 Jan 2016US 9,238,825 B2MedImmune, LLC
- Mrna encoding influenza virus-like particle8 Jan 2026US 2026/0007735 A1Sanofi Pasteur Limited
- Compositions and methods of use thereof for prevention and treatment of influenza infections9 Nov 2023US 2023/0355740 A1The United States of America as represented by the Secretary of Agriculture
- Vaccine using m2/bm2-deficient influenza vectors17 Aug 2023US 2023/0256086 A1FluGen, Inc.
- Novel coronavirus vaccine based on influenza virus vector and preparation method thereof4 May 2023US 2023/0133364 A1Guangzhou N Biomed Co., Ltd.
- Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof23 Mar 2023US 2023/0089695 A1Versitech Limited
Most cited
By later US patents
- Influenza hemagglutinin and neuraminidase variants71US 7,566,458 B2MedImmune, LLC · 2009
- Signal for packaging of influenza virus vectors47US 7,226,774 B2Wisconsin Alumni Research Foundation · 2007
- Recombinant influenza vectors with tandem transcription units41US 7,968,101 B2Wisconsin Alumni Research Foundation · 2011
- Multi plasmid system for the production of influenza virus40US 8,012,736 B2MedImmune, LLC · 2011
- Signal for packaging of influenza virus vector38US 7,585,657 B2Wisconsin Alumni Research Foundation · 2009